In a group-specific comparison of the suPARnosticTM assay and the Quantikine Human uPAR-Immunoassay the mean difference of suPAR levels in FSGS patients was 3.04 ± 1.5 ng/mL (44%; 95% CI, 40 to 48; p < 0.001), in patients with other GN 0.21 ± 1.1 ng/mL (−2%; 95% CI, −11 to 6; p < 0.62) and in healthy controls −0.54 ± 0.3 ng/mL (−43%; 95% CI, −54 to −32; p < 0.001). Here, PLAUR is linked to focal segmental glomerulosclerosis.